98%
921
2 minutes
20
Background: Differences between female and male patients may influence the outcomes of transcatheter aortic valve replacement (TAVR). However, knowledge regarding known sex differences in TAVR procedures among Chinese people remains limited. Therefore, this study aimed to investigate the impact of sex-related differences on reverse left ventricular (LV) remodeling following TAVR in the Chinese population.
Methods: Patients with severe symptomatic aortic stenosis (AS) who underwent TAVR at the Heart Center of the Affiliated Zhongshan Hospital of Dalian University were enrolled. A total of 136 patients who underwent implantation of a self-expandable Venus A valve between 2019 and 2024 were evaluated. We retrospectively compared the clinical outcomes and characteristics of all patients by sex.
Results: In our study, females presented with a smaller body surface area (BSA) (1.68 ± 0.15 m vs. 1.90 ± 0.14 m, < 0.001), aortic valve area (AVA) (0.64 ± 0.22 cm vs. 0.77 ± 0.20 cm, = 0.003), left ventricular end-diastole diameter (LVEDD) (49.72 ± 7.37 mm vs. 53.33 ± 8.36 mm, = 0.023), as well as interventricular septum in diastole (IVSD) (12.85 ± 2.19 mm vs. 13.88 ± 2.61 mm, = 0.034) at baseline. Comparatively, males had larger aortic root structures at baseline and a larger size of valve implantation during the procedure ( < 0.05). However, the indexed AVA was not significantly different between the two groups at baseline. Sex-specific outcomes, particularly AVA, LVEDD, aortic root diameter (AO), and IVSD, were significantly different during each follow-up within the first six months ( < 0.05), indicating that females experienced greater improvements in these echocardiographic characteristics after TAVR. Left ventricular ejection fraction (LVEF) only improved significantly at 1-month follow-up in females compared to males (57.77 ± 7.87% vs. 54.40 ± 8.21%, = 0.037). Multivariable linear-regression analysis showed that being a female patient (Beta: 10.200; 95% CI: 0.075-20.326; = 0.048), as well as having a higher IVSD (Beta: 2.939; 95% CI: 1.110-4.769; = 0.002), and higher baseline left ventricular mass index (LVMi) (Beta: 0.409; 95% CI: 0.298-0.521; < 0.001) were independently associated with greater mid-term LVMi regression post-TAVR.
Conclusions: Female patients with AS exhibited more favorable mid-term LV reverse remodeling post-TAVR compared to male patients in a Chinese population.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12415741 | PMC |
http://dx.doi.org/10.31083/RCM39581 | DOI Listing |
Ann Am Thorac Soc
September 2025
Brigham and Women's Hospital, Division of Sleep and Circadian Disorders, Boston, Massachusetts, United States.
Rationale: There are insufficient data to inform the management of central sleep apnea (CSA) in patients with heart failure (HF) with reduced ejection fraction (HFrEF). Nocturnal oxygen therapy (NOT) has been postulated to benefit CSA patients with HFrEF, but has not been rigorously studied. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.
View Article and Find Full Text PDFAm J Physiol Heart Circ Physiol
September 2025
Department of Medical Pharmacology and Physiology, School of Medicine, University of Missouri.
The sarcomeric protein cardiac myosin binding protein-C (cMyBP-C) binds myosin on thick filaments and regulates cardiac myocyte contraction. Our lab has reported that permeabilized cardiac myocytes lacking cMyBP-C generate greater power and show disproportionately fast sarcomere shortening velocities at high loads. Also, high resolution X-ray diffraction of cardiac trabeculae found that myosin cross-bridges in the cMyBP-C zone are the most active during loaded contractions.
View Article and Find Full Text PDFJAMA Cardiol
September 2025
Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, New York.
Importance: Transthyretin cardiac amyloidosis (ATTR-CA) is an underdiagnosed but treatable cause of heart failure (HF) in older individuals that occurs in the context of normal wild-type (ATTRwt-CA) or an abnormal inherited (ATTRv-CA) TTR gene variant. While the most common inherited TTR variant, V142I, occurs in 3% to 4% of self-identified Black Americans and is associated with excess morbidity and mortality, the prevalence of ATTR-CA in this at-risk population is unknown.
Objective: To define the prevalence of ATTR-CA and proportions attributable to ATTRwt-CA or ATTRv-CA among older Black and Caribbean Hispanic individuals with HF.
JACC Case Rep
September 2025
Cardiovascular Division, Department of Medicine, Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Electronic address:
Baroreflex activation therapy (BAT) improves functional status, quality of life, and exercise capacity in patients with heart failure with reduced ejection fraction; however, its direct effects on reversing adverse cardiac remodeling as assessed by improvements in cardiac structure, function, and coupling with the arterial system remain unclear. We present 2 cases of patients who initially presented with decompensated heart failure, and despite initial medical therapy and continued outpatient follow-up, were unable to tolerate full escalation of guideline-directed medical therapy. The patients remained symptomatic, with high biomarker levels, poor functional capacity, severe heart failure symptoms, and objectively had decreased stroke volume, low left ventricular ejection fraction, and high left ventricular mass.
View Article and Find Full Text PDFExpert Rev Med Devices
September 2025
Rutgers University, New Brunswick, NJ, USA.